ISAL 2019 | Bunctional PD-1 x αCD3 x αCD33 CiTE for AML

Marion Subklewe

Marion Subklewe, MD, of LMU Hospital Munich, Munich, Germany, discusses the bunctional PD-1 x αCD3 x αCD33 checkpoint inhibitory T cell-engaging (CiTE) antibody for acute myeloid leukemia. This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video